These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 23990735)

  • 1. Immunocytokines: a review of molecules in clinical development for cancer therapy.
    List T; Neri D
    Clin Pharmacol; 2013; 5(Suppl 1):29-45. PubMed ID: 23990735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-Homing Antibody-Cytokine Fusions for Cancer Therapy.
    Prodi E; Neri D; De Luca R
    Onco Targets Ther; 2024; 17():697-715. PubMed ID: 39224695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunocytokines: a novel class of potent armed antibodies.
    Pasche N; Neri D
    Drug Discov Today; 2012 Jun; 17(11-12):583-90. PubMed ID: 22289353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy.
    Hutmacher C; Neri D
    Adv Drug Deliv Rev; 2019 Feb; 141():67-91. PubMed ID: 30201522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulating the Antitumor Immune Response Using Immunocytokines: A Preclinical and Clinical Overview.
    Boersma B; Poinot H; Pommier A
    Pharmaceutics; 2024 Jul; 16(8):. PubMed ID: 39204319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
    Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
    Front Immunol; 2018; 9():2905. PubMed ID: 30619269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Cytokine Delivery for Cancer Treatment: Engineering and Biological Effects.
    Rybchenko VS; Aliev TK; Panina AA; Kirpichnikov MP; Dolgikh DA
    Pharmaceutics; 2023 Jan; 15(2):. PubMed ID: 36839658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation.
    Murer P; Neri D
    N Biotechnol; 2019 Sep; 52():42-53. PubMed ID: 30991144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilizing Immunocytokines for Cancer Therapy.
    Runbeck E; Crescioli S; Karagiannis SN; Papa S
    Antibodies (Basel); 2021 Mar; 10(1):. PubMed ID: 33803078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.
    Hess C; Neri D
    Protein Eng Des Sel; 2014 Jun; 27(6):207-13. PubMed ID: 24795343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine Biopharmaceuticals with "Activity-on-Demand" for Cancer Therapy.
    Rotta G; Puca E; Cazzamalli S; Neri D; Dakhel Plaza S
    Bioconjug Chem; 2024 Aug; 35(8):1075-1088. PubMed ID: 38885090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical and clinical development of immunocytokines.
    Sondel PM; Hank JA; Gan J; Neal Z; Albertini MR
    Curr Opin Investig Drugs; 2003 Jun; 4(6):696-700. PubMed ID: 12901228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins.
    Xiang J
    Hum Antibodies; 1999; 9(1):23-36. PubMed ID: 10331183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel strategy to generate immunocytokines with activity-on-demand using small molecule inhibitors.
    Rotta G; Gilardoni E; Ravazza D; Mock J; Seehusen F; Elsayed A; Puca E; De Luca R; Pellegrino C; Look T; Weiss T; Manz MG; Halin C; Neri D; Dakhel Plaza S
    EMBO Mol Med; 2024 Apr; 16(4):904-926. PubMed ID: 38448543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-cytokine fusion proteins for improving efficacy and safety of cancer therapy.
    Valedkarimi Z; Nasiri H; Aghebati-Maleki L; Majidi J
    Biomed Pharmacother; 2017 Nov; 95():731-742. PubMed ID: 28888210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant immunocytokines targeting the mouse transferrin receptor: construction and biological activities.
    Dreier T; Lode HN; Xiang R; Dolman CS; Reisfeld RA; Kang AS
    Bioconjug Chem; 1998; 9(4):482-9. PubMed ID: 9667950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
    Vijayakumar G; McCroskery S; Palese P
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
    Fournier P; Schirrmacher V
    BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity.
    Neri D
    Cancer Immunol Res; 2019 Mar; 7(3):348-354. PubMed ID: 30824549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.